Retrophin Inc (RTRX) Given Average Rating of “Hold” by Analysts

Shares of Retrophin Inc (NASDAQ:RTRX) have received a consensus rating of “Hold” from the six analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $44.00.

RTRX has been the subject of several research analyst reports. BidaskClub cut shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Saturday, December 30th. Zacks Investment Research upgraded shares of Retrophin from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 4th. Finally, ValuEngine cut shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Saturday, February 3rd.

Retrophin (NASDAQ:RTRX) opened at $22.75 on Monday. The company has a quick ratio of 3.74, a current ratio of 3.80 and a debt-to-equity ratio of 0.15. Retrophin has a 1 year low of $15.55 and a 1 year high of $26.44. The firm has a market cap of $903.02, a P/E ratio of -13.62 and a beta of 0.96.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.20). Retrophin had a negative return on equity of 13.98% and a negative net margin of 38.55%. The company had revenue of $42.18 million during the quarter, compared to the consensus estimate of $42.20 million. analysts expect that Retrophin will post -1.59 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. Prudential Financial Inc. raised its position in shares of Retrophin by 385.7% during the 3rd quarter. Prudential Financial Inc. now owns 194,140 shares of the biopharmaceutical company’s stock valued at $4,832,000 after acquiring an additional 154,170 shares during the last quarter. Consonance Capital Management LP raised its position in shares of Retrophin by 4.0% during the 4th quarter. Consonance Capital Management LP now owns 3,644,438 shares of the biopharmaceutical company’s stock valued at $76,788,000 after acquiring an additional 138,834 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Retrophin by 8.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 896,815 shares of the biopharmaceutical company’s stock valued at $22,322,000 after acquiring an additional 71,562 shares during the last quarter. Bank of Montreal Can raised its position in shares of Retrophin by 51.5% during the 4th quarter. Bank of Montreal Can now owns 181,416 shares of the biopharmaceutical company’s stock valued at $3,823,000 after acquiring an additional 61,634 shares during the last quarter. Finally, GW&K Investment Management LLC raised its position in shares of Retrophin by 40.7% during the 4th quarter. GW&K Investment Management LLC now owns 190,545 shares of the biopharmaceutical company’s stock valued at $4,015,000 after acquiring an additional 55,130 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Retrophin Inc (RTRX) Given Average Rating of “Hold” by Analysts” was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3300928/retrophin-inc-rtrx-given-average-rating-of-hold-by-analysts.html.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Husky Energy  Posts Quarterly  Earnings Results, Misses Expectations By $0.05 EPS
Husky Energy Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS
KingN Coin  Price Up 28.5% This Week
KingN Coin Price Up 28.5% This Week
LiteDoge Market Capitalization Tops $2.71 Million
LiteDoge Market Capitalization Tops $2.71 Million
FujiCoin  Trading 33.1% Higher  Over Last 7 Days
FujiCoin Trading 33.1% Higher Over Last 7 Days
Analysts Expect Casella Waste Systems  Will Post Earnings of -$0.01 Per Share
Analysts Expect Casella Waste Systems Will Post Earnings of -$0.01 Per Share
Iron Mountain  Issues  Earnings Results
Iron Mountain Issues Earnings Results


© 2006-2018 Ticker Report. Google+.